http://www.biospace.comBioSpace RSS GeneratorFri, 24 May 2013 16:35:32 GMT20http://rss.biospace.com/images/BSPLogo.gifhttp://www.BioSpace.com/news.aspx?SectionId=1Copyright (C) 2011http://www.bloomberg.com/news/2013-05-19/-love-hormone-promises-safer-births-after-pfizer-flop.html?cmpid=yhooStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>A hormone treatment based on technology used in Pfizer (PFE) Inc.s failed inhalable insulin shows promise in fighting the leading cause of maternal mortality. Six years after Pfizer pulled Exubera from the...Tue, 21 May 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130521005859&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>SAN FRANCISCO--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced results from a preliminary analysis that showed statistically significant reductions ...Tue, 21 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291049&full=1JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (TEVA) and H. Lundbeck A/S announced today that a double-blind, placebo controlled, randomized, multicenter study of Azilect (rasagiline tablets) met its primary endpoint. The study, known as ANDANTE (Add oN to Dopamine AgoNists in the TrEatment of Parkinsons disease), assessed the efficacy and tolerability of Azilect as add-on treatment...Wed, 20 Mar 2013 12:00:00 AM GMThttp://www.pmlive.com/pharma_news/bayers_eylea_data_unreliable,_says_iqwig_468241Bayer and Regeneron received a blow last week when Germany's cost effectiveness watchdog turned down their eye disorder drug Eylea after ruling that it did not provide enough benefit compared to current treatments. The German health technology assessment (HTA) body IQWiG released a statement on Friday claiming that, following an assessment of the benefits of Eylea (aflibercept), current data was unable...Wed, 20 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=290742&full=1Basel, 18 March 2013 -- Roche's Pegasys receives EU approval for the treatment of chronic hepatitis C in children five years of age and older</p><p>Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency (EMA) has expanded the approval of Pegasys (peginterferon alfa-2a) plus ribavirin for the treatment of chronic hepatitis C virus (HCV). The new label includes children...Mon, 18 Mar 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20130317005003&newsLang=enSAINT-PREX, Switzerland--(BUSINESS WIRE)--Data presented today at the European Association of Urology (EAU) 2013 annual meeting in Milan, indicate that the gonadotropin releasing hormone (GnRH) antagonist degarelix (brand name: FIRMAGON) may be associated with lower risk of a cardiovascular (CV) event or death compared to commonly prescribed luteinising hormone-releasing hormone (LHRH) agonists....Mon, 18 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=290009&full=1SAN FRANCISCO--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, today announced that researchers from the Clinical Trial Service Unit at Oxford University presented results from the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study of TREDAPTIVE(extended-release niacin/laropiprant) during a late-breaking clinical...Mon, 11 Mar 2013 12:00:00 AM GMThttp://www.pharmatimes.com/Article/13-03-11/AbbVie_sues_EMA_to_stop_release_of_Humira_data.aspxAbbVie Inc. (ABBV), the drugmaker that was split off from Abbott Laboratories (ABT) at the start of this year, sued the European Unions pharmaceuticals regulator in a bid to block publication of clinical-trial data. AbbVie, based in North Chicago, Illinois, filed two lawsuits against the European Medicines Agency at the European Union General Court in Luxembourg seeking to protect AbbVies confidential...Mon, 11 Mar 2013 12:00:00 AM GMThttp://www.bloomberg.com/news/2013-03-06/roche-s-rituxan-cures-rare-skin-blistering-disease-in-study.htmlRoche Holding AG (ROG)s top-selling drug Rituxan effectively cured most cases of a rare and deadly skin disease in a patient study that suggests the medicine may replace steroids as the standard treatment. In a trial among 22 people with severe pemphigus, a disorder marked by blisters on the skin and in the mouth and genitals, 59 percent were symptom-free more than six years after treatment with a...Fri, 08 Mar 2013 12:00:00 AM GMThttp://www.pmlive.com/pharma_news/discount_convinces_nice_to_uphold_recommendation_for_novartis_xolair_466412The National Institute for Health and Clinical Excellence (NICE) has backed down on draft guidance to withdraw its recommendation for Novartis' Xolair in the treatment of asthma. The cost-effectiveness body for England and Wales said in November 2012 that, in the light of new evidence following changes to the drug's dosing schedule, it was no longer able to recommend Xolair (omalizumab) for severe...Thu, 07 Mar 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20130220006819&newsLang=enINGELHEIM, Germany--(BUSINESS WIRE)--For Non-US, Non-UK & Non-Canadian Media Only Today, the New England Journal of Medicine published findings from the RE-MEDYTM and RE-SONATETM trials investigating Pradaxa (dabigatran etexilate) in the long-term prevention of deep vein thrombosis (DVT) or pulmonary embolism (PE). The results demonstrate that Pradaxa 150 mg twice daily is an effective option with...Thu, 21 Feb 2013 12:00:00 AM GMThttp://www.foxbusiness.com/news/2013/01/24/pfizer-reports-positive-results-in-studies-toviaz-pristiq-chantix/Pfizer Inc. (PFE) reported positive results in studies of an extended-release version of its Pristiq depression treatment, a higher dosage of its Toviaz urinary incontinence drug as well as the efficacy of smoking-cessation treatment Chantix among smokers whose previous attempts to quit have failed.Thu, 24 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=284529&full=1EAST HANOVER, N.J.</span>, <span class"xn-chron">Jan. 10, 2013</span> /PRNewswire/ -- Data published today in <i>The Lancet</i> showed that patients on Afinitor (everolimus) tablets with non-cancerous kidney tumors known as renal angiomyolipomas associated with tuberous sclerosis complex (TSC) experienced a significant reduction in tumor size and the absence of tumor progression<sup>...Fri, 11 Jan 2013 12:00:00 AM GMThttp://www.reuters.com/article/2012/12/21/merck-cholesterol-regulation-idUSL5E8NL4DK20121221?type=companyNews&feedType=RSS&feedName=companyNews&rpc=43The European Medicines Agency said it has launched a review of Merck & Co Inc's cholesterol drug Tredaptive after the medicine failed a U.S. trial assessing its effectiveness and safety. Although the commercial fallout from any decision to pull the drug from the market in Europe would be limited, it would be a blow to Merck's reputation. Bernstein analyst Tim Anderson estimates that Tredaptive sales...Wed, 26 Dec 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=282550&full=1PRLog (Press Release) - Dec. 17, 2012 - Immune Response BioPharma, Inc. Files for Orphan Designation of REMUNE for Pediatric HIV/AIDS.Immune Response BioPharma, Inc. Today announces plans to introduce REMUNE therapeutic vaccine into the area of pediatric treatment options for patients suffering from Pediatric HIV/AIDS as a safe alternative HAART.</p><p>Pediatric HIV/AIDS is a disease afflicting...Thu, 13 Dec 2012 12:00:00 AM GMThttp://www.reuters.com/article/2012/12/11/us-novonordisk-obesity-idUSBRE8BA0FM20121211Denmark's Novo Nordisk is sizing up a high-price niche market for its drug liraglutide as a weight-loss treatment, with the United States the prime opportunity. The premium-price approach could turn it into a multibillion-dollar-a-year product, the company believes. Novo is studying the injected drug - already on the market as a treatment for type-2 diabetes under the brand name Victoza - as a therapy...Wed, 12 Dec 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=281720&full=1MISSISSAUGA, ON, Dec. 10, 2012 /CNW/ - Roche today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy...Tue, 11 Dec 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20121211005826&newsLang=enBOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Srl (NASDAQ: CELG) today announced results from an analysis of post-progression outcomes in MM-015, a phase III study of continuous REVLIMID (lenalidomide) plus melphalan and prednisone (MPR-R, n152) compared with a fixed cycle of MPR followed by placebo (n153) or of melphalan and prednisone followed by placebo (MP, n-154) in newly diagnosed...Tue, 11 Dec 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20121210006553&newsLang=enBOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Srl (NASDAQ: CELG) today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (azacitidine) in patients 60 years or older with untreated acute myeloid leukemia (AML) were presented at the American Society of Hematology annual meeting in Atlanta, GA. In the phase II investigator-initiated study...Tue, 11 Dec 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20121210005582&newsLang=enINGELHEIM, Germany--(BUSINESS WIRE)-- Results from a new post-hoc analysis of the landmark RE-LYi trial show that in patients experiencing a major bleeding event, treatment with Pradaxa (dabigatran etexilate) was associated with lower mortality and a shorter length of stay in intensive care compared to warfarin. In a pooled post-hoc analysis of five Phase III trials with Pradaxa, the data show a...Mon, 10 Dec 2012 12:00:00 AM GMThttp://www.vancouversun.com/health/Pharma+company+says+acted+appropriately+response+Paxil+classaction/7661880/story.htmlPharmaceutical giant GlaxoSmithKline says it conducted its clinical trial program for the anti-depressant drug Paxil appropriately in marketing the medicine for use by women of childbearing age. The statement comes after a B.C. Supreme Court judge certified a class-action lawsuit launched by a British Columbia mother whose daughter was born with a hole in her heart. Lawyers allege the drug caused birth...Fri, 07 Dec 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20121205005735&newsLang=enWILMINGTON, Del.--(BUSINESS WIRE)--Today, updated overall survival (OS) data for FASLODEX (fulvestrant) Injection in patients with hormone receptor-positive advanced breast cancer whose disease progressed or recurred following prior endocrine therapy was presented at the 35th CTRC-AACR San Antonio Breast Cancer Symposium by the principal investigator, Angelo Di Leo, MD, Head of the Sandro Pitigliani...Wed, 05 Dec 2012 12:00:00 AM GMThttp://www.reuters.com/article/2012/11/28/us-cialis-muscular-dystrophy-idUSBRE8AR15P20121128Eli Lilly's erectile dysfunction drug Cialis can correct abnormal blood flow in patients with a certain type of muscular dystrophy and could in future be used to slow progression of the disorder, researchers said on Wednesday. The findings suggest that while Cialis can't cure the condition, known as Becker muscular dystrophy, it could be used as a treatment to slow or prevent muscle weakening and help...Fri, 30 Nov 2012 12:00:00 AM GMThttp://www.reuters.com/article/2012/11/28/us-deaths-more-idUSBRE8AR0KO20121128A popular heart drug used to control abnormal heart rates may cause patients who take it to die earlier, according to a new study. The study, which was published online in the European Heart Journal on Nov. 27, 2012, showed that patients who took digoxin who had atrial fibrillation (AF) -- a condition where the heart's upper chambers flutter erratically -- died in significant numbers while on the medication...Wed, 28 Nov 2012 12:00:00 AM GMThttp://www.zenopa.com/news/801495437/Novo_Nordisk_reports_positive_data_from_Victoza_analysesDenmark's Novo Nordisk on Tuesday said new data showed an advantage for type two diabetes patients given its diabetes drug Victoza compared with rival drugs from Merck & Co and Amylin Pharmaceuticals Inc. The world's biggest insulin producer said in a statement that more type two diabetes patients given Victoza achieved an average blood sugar level below seven percent than those given Merck's sitagliptin...Tue, 27 Nov 2012 12:00:00 AM GMThttp://www.pharmatimes.com/Article/12-11-19/Roche_positive_about_Avastin_in_new_brain_cancer_cases.aspxA new study of Roche's Avastin has shown the drug can extend progression-free survival (PFS) by more than four months when added onto standard therapy for an aggressive form of brain cancer. The AVAglio trial found that adding Avastin (bevacizumab) to radiation and temozolomide chemotherapy reduced the risk of cancer progression by 36 per cent, extending PFS from 6.2 months with placebo to 10.6 months...Fri, 23 Nov 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20121115005790&newsLang=enGLASGOW, England--(BUSINESS WIRE)--Gilead Sciences (Nasdaq:GILD) today announced Phase 3b clinical trial results from STaR (Single Tablet Regimen), the first head-to-head study comparing the single tablet regimens Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) and Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) in treatment-nave adults with HIV infection. Data...Thu, 15 Nov 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20121115005788&newsLang=enGLASGOW, England--(BUSINESS WIRE)--Gilead Sciences (Nasdaq:GILD) today announced two-year (96-week) results from two pivotal Phase 3 studies (Studies 102 and 103) evaluating the companys newest single tablet HIV regimen, StribildTM (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), among treatment-nave patients with HIV-1 infection. Data show that Stribild...Thu, 15 Nov 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20121108005079&newsLang=enINGELHEIM, Germany--(BUSINESS WIRE)--For Non-U.S. and Non-U.K. Media -- Boehringer Ingelheim and Eli Lilly and Company are pleased to announce that the recruitment of patients for CAROLINA (Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes)1 has been completed. Linagliptin is currently the only DPP-4 inhibitor that is being compared to an active comparator...Thu, 08 Nov 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20121108005651&newsLang=enLOS ANGELES--(BUSINESS WIRE)-- 8 November, 2012--Pivotal data from the RELY-ABLE study have provided additional data to support the long-term safety profile and efficacy of Pradaxa (dabigatran etexilate) for stroke prevention in patients with non-valvular atrial fibrillation (AF).*1 The new long-term results presented at the American Heart Associations (AHA) Scientific Sessions, are highly consistent...Thu, 08 Nov 2012 12:00:00 AM GMThttp://www.bloomberg.com/news/2012-11-05/novartis-drug-works-to-treat-rare-cushing-s-disease.htmlNovartis AG (NOVN)s treatment for Cushings disease works, potentially providing a second marketed therapy for the rare condition, U.S. regulators said. The drug known as pasireotide decreases levels of the hormone cortisol, which in excess cause Cushings, Food and Drug Administration staff said today in a report. The disease leads to obesity, skin that bruises easily, excess hair growth in women...Tue, 06 Nov 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20121106005165&newsLang=enINGELHEIM, Germany--(BUSINESS WIRE)--New real-world data reinforces the positive safety and efficacy profile of Pradaxa (dabigatran etexilate) in clinical practice for the prevention of venous thromboembolism (VTE) in patients undergoing total knee or hip replacement.* Data presented today at the 2012 American Heart Association Scientific Sessions highlight that treatment with Pradaxa was well tolerated...Tue, 06 Nov 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20121105006141&newsLang=enINGELHEIM, Germany--(BUSINESS WIRE)--For Non-US, Non-UK & Non-Canadian Media Only: Following independent regulatory appraisals of the safety and efficacy of the anticoagulation therapy Pradaxa, both the U.S. Food and Drug Administration (FDA) and European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) have reconfirmed the positive benefit-risk profile of the treatment...Mon, 05 Nov 2012 12:00:00 AM GMThttp://www.bloomberg.com/news/2012-11-01/glaxo-roche-drugs-help-treat-breast-cancer-in-brain.htmlGlaxoSmithKline (GSK) Plcs breast cancer pill Tykerb, used with Roche Holding AG (ROG)s drug Xeloda, helped treat the diseases spread to the brain, according to a study.<br><br>The treatments shrank the size of brain tumors by at least 50 percent in two-thirds of the patients studied, according to a trial funded by London-based Glaxo and published today in the Lancet Oncology journal. The research...Fri, 02 Nov 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20121031005562&newsLang=enINGELHEIM, Germany--(BUSINESS WIRE)-- Widely anticipated results from RELY-ABLE, the first long-term follow-up study of a novel oral anticoagulant treatment for stroke prevention in AF, will be among the numerous clinical reports on Pradaxa (dabigatran etexilate) to be presented at the American Heart Associations (AHA) Scientific Sessions in Los Angeles from 3-7 November.1 The wealth of evidence...Wed, 31 Oct 2012 12:00:00 AM GMThttp://www.bloomberg.com/news/2012-10-25/novartis-cannibalizes-gleevec-to-boost-new-cancer-drug.html<a href"http://www.biospace.com/company_profile.aspx?CompanyId1011873&typepartner&sourceNewsStoryProfile"><b>Novartis</b></a> | <a href"http://www.biospace.com/jobs/search-results/CustomerId209270?typepartner&sourceNewsStoryJobs"><b>Jobs at Novartis Pharmaceuticals</b></a><br><br><a href"http://www.biospace.com/company_profile.aspx?CompanyId1002633&typepartner&sourceNewsStoryProfile...Mon, 29 Oct 2012 12:00:00 AM GMThttp://www.reuters.com/article/2012/10/19/us-glaxo-pandemrix-idUSBRE89I0HX20121019One year after restricting usage of the Pandremix vaccine over concerns there was a link to narcolepsy, the European Medicines Agency has decided there is insufficient evidence to confirm the notion that a cause-and-effect association exists. The vaccine was widely used in 2009 to combat the H1N1 influenza outbreak and 30 million people were vaccinated in the EU.Fri, 19 Oct 2012 12:00:00 AM GMThttp://www.streetinsider.com/FDA/Arena+(ARNA)+Partner+Eisai+May+Also+Have+Promising+Weight-Loss+Pill+in+the+Works/7795425.htmlEisai Co.s epilepsy drug Zonegran helped obese people lose weight, according to a study that shows the potential of another antiseizure medication to aid in weight reduction. Obese people who took 400 milligrams of Zonegran a day for a year had a 3.3 kilograms (7.3 pounds) greater weight loss than those on a placebo, according to the study published today in Archives of Internal Medicine. The efficacy...Wed, 17 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=275888&full=1CAMBRIDGE, Mass. October 12, 2012 Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) announced today that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). In the study, once-daily, oral AUBAGIO 14 mg significantly reduced the annualized relapse rate and slowed progression of disability in...Mon, 15 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=275912&full=1Basel, October 12, 2012 - New data will be presented at the 28th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) that reinforce the generally early and sustained efficacy benefit and long-term safety profile for GilenyaR (fingolimod), the first once-daily oral therapy approved to treat relapsing forms of multiple sclerosis (MS)[1],[2].</p><p>"As the...Fri, 12 Oct 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20121010006619&newsLang=enWESTON, Mass. & DUBLIN--(BUSINESS WIRE)--Today, Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that results from 11 company-sponsored TYSABRI presentations, including 10 posters and one platform, will be available for viewing at the 28TH Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10 13. Key data...Thu, 11 Oct 2012 12:00:00 AM GMThttp://www.rttnews.com/1978734/sanofi-says-jco-publishes-positive-velour-study-results-of-cancer-drug-zaltrap.aspx?type=bn&utm_source=google&utm_campaign=sitemapFrench drug giant Sanofi S.A. (SNY: Quote) on Monday said the detailed positive results from the pivotal Phase III VELOUR study evaluating ZALTRAP (aflibercept) Injection for Intravenous Infusion for patients with previously treated metastatic colorectal cancer were published in the October 2012 edition of the Journal of Clinical Oncology or JCO. The company said the latest data supported the regulatory...Tue, 09 Oct 2012 12:00:00 AM GMThttp://www.rttnews.com/1978221/sanofi-s-lantus-insulin-more-potent-to-maintain-blood-sugar-in-type-2-diabetes.aspx?type=bnSanofi said its top-selling Lantus insulin treatment proved three times more likely than standard care to maintain targeted blood sugar levels in patients with pre-diabetes or early type 2 diabetes at high risk of heart disease. This was based on a six-year clinical trial called "Origin" that involved more than 12,500 participants, Sanofi said on Friday. The data was presented to the annual meeting...Fri, 05 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=274553&full=1ZURICH--Roche Holding AG (ROG.VX) and the Breast International Group Monday announced final results from the Phase III HERA trial, which confirmed that one year of Herceptin (trastuzumab) treatment remains the standard of care for people with early-stage HER2-positive breast cancer.</p><p>MAIN FACTS:</p><p>- These data showed that there was no difference in the time women lived without their...Mon, 01 Oct 2012 12:00:00 AM GMThttp://www.thestreet.com/story/11722819/1/celgenes-abraxane-is-talk-of-european-cancer-confab.html?cm_ven=GOOGLENCelgene (CELG) hasn't yet announced results from the Abraxane phase III study in pancreatic cancer but the drug generated a lot of positive buzz at this weekend's European Society of Medical Oncology (ESMO) conference. Cancer consultant guru and blogger Sally Church, in attendance at ESMO, notes oncologists who specialize in pancreatic cancer are typically a dour lot because of the paucity of effective...Mon, 01 Oct 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20120928005225&newsLang=enBEERSE, Belgium--(BUSINESS WIRE)--For medical media only -- A series of data presentations released today at the 21st European Academy of Dermatology and Venereology (EADV) congress, in Prague, Czech Republic, demonstrate that STELARA (ustekinumab) is effective, well tolerated and improved quality of life in patients with moderate to severe plaque psoriasis. Specifically, efficacy results from the...Fri, 28 Sep 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20120912005915&newsLang=enINGELHEIM, Germany--(BUSINESS WIRE)-- New findings presented at the 2nd Asia Pacific Stroke Conference in Tokyo, Japan, have confirmed that in Asian populations, Pradaxa(dabigatran etexilate) offers considerable benefits for the management of patients with atrial fibrillation (AF) from this region.1 The new sub-analysis of the RE-LY* trial2,3 demonstrates consistently superior efficacy of Pradaxa...Wed, 12 Sep 2012 12:00:00 AM GMThttp://www.zenopa.com/news/801442720/Novartis_data_highlights_benefits_of_individualised_LucentisBasel, September 5, 2012 - New data for LucentisR (ranibizumab), the only anti-VEGF therapy licensed across three ocular indications, show that individualized treatment with Lucentis provides sustained improvement in vision with a low number of injections. It is estimated that over 80% of visual impairment is preventable when due to conditions such as wet age-related macular degeneration (wet AMD...Wed, 05 Sep 2012 12:00:00 AM GMThttp://www.businessweek.com/news/2012-08-28/novartis-smoker-s-cough-treatment-beats-glaxo-s-advair-in-trialPatients taking Novartis AG (NOVN)s experimental once-daily treatment for smokers cough showed a significant improvement in lung function over those on an existing medicine marketed by GlaxoSmithKline Plc (GSK), which is also developing a successor drug. Patients taking Novartiss QVA149 were able to expel 100 milliliters (3.4 ounces) more air from their lungs in one second than those receiving Glaxo...Wed, 29 Aug 2012 12:00:00 AM GMThttp://www.thepharmaletter.com/file/116002/bayer-and-jjs-xarelto-aids-survival-after-heart-attack.htmlBayer said results from a late-stage clinical trial showed its anti-clotting pill Xarelto cut the risk of recurrence in patients who have suffered a severe heart attack, as it strives to secure U.S. approval for wider use of the drug. Results from the trial showed that adding Xarelto to standard therapy - typically aspirin and Sanofi's Plavix - significantly reduced cardiovascular death, heart attack...Wed, 29 Aug 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=271161&full=1<div id"releaseBody"><p>MUNICH, GERMANY--(Marketwire - August 28, 2012) - Updated treatment guidelines presented by a leading European acute cardiology expert task force on the management of a severe form of heart attack called ST-segment elevation acute myocardial infarction (STEMI) recommend the use of bivalirudin (The Medicines Company (NASDAQ: <a href"http://www.marketwire.com/mw/stock...Tue, 28 Aug 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20120827006111&newsLang=enLONDON--(BUSINESS WIRE)--AstraZeneca today announced that ticagrelor, an oral antiplatelet medicine, received a Class I recommendation from the European Society of Cardiology (ESC) in the revised Guidelines on the Management of Acute Myocardial Infarction in Patients Presenting with Persistent ST-Segment Elevation (STEMI) guidelines. Ticagrelor is known as BRILIQUE in the European Union and BRILINTA...Tue, 28 Aug 2012 12:00:00 AM GMThttp://www.rttnews.com/1954059/daiichi-lilly-say-heart-drug-effient-fails-to-meet-goal-in-a-phase-iii-trial.aspx?type=bn&utm_source=google&utm_campaign=sitemapDaiichi Sankyo Co., Ltd. (DSKYF, DSNKY) and Eli Lilly and Co. (LLY:Quote) Sunday announced that their new heart drug Effient (prasugrel) failed to beat the older product Plavix (clopidogrel). The study named TRILOGY ACS did not meet primary objective of demonstrating prasugrel superiority over clopidogrel. Daiichi Sankyo and Eli Lilly co-developed Effient, an oral antiplatelet agent discovered by Daiichi...Mon, 27 Aug 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20120824005211&newsLang=enINGELHEIM, Germany--(BUSINESS WIRE)-- In the absence of a head-to-head study, a comprehensive analysis published in Thrombosis and Hemostasis,1 looks into the efficacy and cost-effectiveness of Pradaxa for stroke prevention in patients with non-valvular atrial fibrillation in an indirect comparison to rivaroxaban. The analysis, based on two large scale trials including more than 32.000 patients combined...Fri, 24 Aug 2012 12:00:00 AM GMThttp://www.rttnews.com/1945269/pfizer-s-phase-3-study-of-torisel-in-combination-with-bevacizumab-fails.aspx?type=qfNEW YORK--(BUSINESS WIRE)-- Pfizer Inc. announced today that the Phase 3 INTORACT trial (B1771006), evaluating the combination of bevacizumab plus TORISEL (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-a-2a) in the first-line treatment of patients with advanced renal cell carcinoma (RCC) across risk groups, did not meet its primary endpoint of superiority in extending progression...Mon, 13 Aug 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=269860&full=1<div id"releaseBody"><p>OSLO, NORWAY--(Marketwire - August 13, 2012) - <table class"releaseLink"><tr><td class"releaseLink"><b>Highlighted Links</b></td></tr><tr><td><p>&nbsp;</p><a href"http://www2.marketwire.com/mw/mmframe?prid919016&attachid2063976">Bionor Pharma Company Website</a></td></tr></table> Bionor Pharma ASA (OSLO: BIONOR)<p><b>News Summary</b><p><ul><li><b>Placebo...Mon, 13 Aug 2012 12:00:00 AM GMThttp://www.genengnews.com/gen-news-highlights/some-better-news-for-avastin/81247168/Swiss drugmaker Roche Holding AG said a new study of cancer drug Avastin showed it significantly extended progression-free survival of people with an aggressive form of brain cancer. The Phase III AVAglio study met one of its main targets of improving progression-free survival in people with glioblastoma, Roche, the world's largest maker of cancer drugs, said in a statement on Friday. "This study showed...Fri, 10 Aug 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20120730006110&newsLang=enPRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced the results of analyses showing that Onglyza(saxagliptin) 5 mg demonstrated improvements across key measures of blood sugar control (glycosylated hemoglobin levels, or HbA1c; fasting plasma glucose, or FPG and post-prandial glucose, or PPG) compared to placebo in adult patients with...Mon, 30 Jul 2012 12:00:00 AM GMThttp://www.reuters.com/article/2012/07/24/us-fda-roche-idUSBRE86N0TS20120724Roche Holding AG (ROG)s Lucentis works to treat a leading cause of blindness associated with diabetes, U.S. regulators said. The injection improved vision in people with diabetic macular edema, Food and Drug Administration staff said in a report today ahead of a July 26 meeting of agency advisers on expanding approval of Lucentis. The drug is already used to treat wet age-related macular degeneration...Wed, 25 Jul 2012 12:00:00 AM GMThttp://www.rttnews.com/1923871/astrazeneca-plans-to-conduct-new-study-of-brilinta-in-pad-patients.aspx?type=qf&utm_source=google&utm_campaign=sitemapLONDON, Jul 17, 2012 (BUSINESS WIRE) -- AstraZeneca today announced plans to conduct the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease (PAD), a condition affecting approximately 27 million people in Europe and North America.(1)PAD patients are at high risk of myocardial infarction (MI), strokes, and other health complications. EUCLID is designed to evaluate...Wed, 18 Jul 2012 12:00:00 AM GMThttp://www.zenopa.com/news/801404909/GlaxoSmithKline_reports_positive_phase_III_data_for_HIV_drugAn experimental treatment for HIV developed by GlaxoSmithKline Plc (GSK), Pfizer Inc. (PFE) (PFE) and Shionogi & Co. (4507) reduced the virus in more people than Gilead Sciences Inc. (GILD) (GILD)s Atripla, suggesting it may supplant the worlds best-selling AIDS medicine as the preferred front-line therapy. After 48 weeks of treatment, 88 percent of patients receiving a combination of dolutegravir...Wed, 11 Jul 2012 12:00:00 AM GMThttp://www.rttnews.com/1917294/merck-kgaa-s-cancer-drug-erbitux-fails-in-gastric-cancer-study.aspx?type=qfMerck KGaAs Erbitux cancer treatment failed to help patients with advanced stomach tumors in a late- stage clinical trial, dealing the company a setback in the effort to expand sales of its second-biggest-selling medicine. The drug, combined with two other medicines, didnt extend the length of time that patients lived without their disease getting worse, the Darmstadt, Germany-based company said...Fri, 06 Jul 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20120701005063&newsLang=enUPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (Orexo) has ahead of schedule completed a crucial comparative bioavailability study for its product OX219. The market in the US alone for this type of treatment for people addicted to opioid pain killers, amounted to USD 1.3 bn in 2011. The study, which met the expectations of the key pharmacokinetic parameters, was completed on June 3...Mon, 02 Jul 2012 12:00:00 AM GMThttp://www.rttnews.com/1913888/shire-s-vpriv-shows-improvement-in-gaucher-related-bone-disease-quick-facts.aspx?type=qfNYON, <span class"xn-location">Switzerland</span>, <span class"xn-chron">June 28, 2012</span> /PRNewswire/ --</p><p>Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today presented new data that show VPRIV<b></b> (velaglucerase alfa for injection), the company's enzyme replacement therapy for type 1 Gaucher disease, significantly improved selected markers...Thu, 28 Jun 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20120625005970&newsLang=enINGELHEIM, Germany--(BUSINESS WIRE)-- Findings from an analysis of four Phase III trials, comparing Pradaxa to enoxaparin recently published in Thrombosis Research, support the positive safety profile of Pradaxafor the prevention of venous thromboembolism (VTE) in patients undergoing total knee or hip arthroplasty. The results demonstrate that the risk of acute coronary syndrome (ACS) events was...Mon, 25 Jun 2012 12:00:00 AM GMThttp://www.rttnews.com/1910822/genentech-says-perjeta-combination-increased-survival-in-breast-cancer-patients.aspx?type=bnBusiness Wire -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that people with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA...Fri, 22 Jun 2012 12:00:00 AM GMThttp://www.streetinsider.com/Corporate+News/FDA+Says+More+Data+Needed+for+Sanofis+%28SNY%29+Semuloparin+in+Chemo+Patients/7522899.htmlU.S. drug reviewers questioned the value of preventing blood clots with Sanofi SA's semuloparin injection for cancer patients receiving chemotherapy. The Food and Drug Administration staff said only a small number of people in the clinical trials for semuloparin actually had issues with clotting, and most people died from other problems. "These findings call into question the clinical value of semuloparin...Mon, 18 Jun 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20120614006349&newsLang=enGUILDFORD, England--(BUSINESS WIRE)--Sanofi presented results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention) at the American Diabetes Association 72nd Scientific sessions. The key findings showed that, compared to standard care, Lantus (insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes...Fri, 15 Jun 2012 12:00:00 AM GMThttp://well.blogs.nytimes.com/2012/06/11/popular-diabetes-drugs-carry-vision-risks/British researchers report that thiazolidinediones, diabetes medications that are used to help control blood sugar levels, may cause eye problems in those who take them. The drugs that fall into this group include Avandia and Actos, which have been tied to increased risk of heart attack in the case of Avandia and bladder cancer in the case of Actos. Now it is possible that these drugs may also cause...Wed, 13 Jun 2012 12:00:00 AM GMThttp://www.rttnews.com/1904143/sanofi-announces-results-of-origin-trial.aspx?type=qf<div id"releaseBody"><p>PARIS, FRANCE--(Marketwire - June 11, 2012) - Sanofi (EURONEXT: SAN) (NYSE: <a href"http://www.marketwire.com/mw/stock.jsp?TickerSNY">SNY</a>) announced today results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention), which showed that Lantus&#174; (insulin glargine [rDNA] injection) had no statistically significant positive or...Tue, 12 Jun 2012 12:00:00 AM GMThttp://www.reuters.com/article/2012/06/11/us-novonordisk-idUSBRE85A05U20120611The world's largest insulin maker Novo Nordisk A/S (NOVO-B.KO) said late Sunday fresh study results show that its diabetes 2-treating drug Victoza more efficiently lowers blood sugar levels and helps patients lose weight than key competitors' drugs. According to the "real world" study, which is based on the treatment of 1,114 British diabetes patients, the use of Victoza resulted in a greater reduction...Tue, 12 Jun 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=263522&full=1<div id"releaseBody"><p>PARIS, FRANCE--(Marketwire - June 11, 2012) - Sanofi (EURONEXT PARIS: SAN) (NYSE: <a href"http://www.marketwire.com/mw/stock.jsp?TickerSNY">SNY</a>) today announced new results of a large-scale epidemiological program, conducted by independent researchers in the northern European countries, at Kaiser Permanente in Northern and Southern California, and at the University...Tue, 12 Jun 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.b30484b92e958b11adda3242e6908a0c/index.jsp?ndmViewId=news_view&newsId=20120612005221&newsLang=enDUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced that Janssen Research & Development, LLC has initiated a phase 3 clinical research program for a three-month formulation of INVEGASUSTENNA (paliperidone palmitate), an injectable medicine for the treatment of schizophrenia. The investigational product is being developed by Janssen Pharmaceutica, NV, licensee to Alkermes proprietary...Tue, 12 Jun 2012 12:00:00 AM GMThttp://www.pharmatimes.com/Article/12-06-11/Novo_Sanofi_report_fresh_diabetes_data_at_ADA.aspxNovo Nordisk and Sanofi are among the companies which have been presenting data on their investigational and already-marketed drugs at the American Diabetes Association conference in Philadelphia. First up, Novo reported results comparing degludec, its ultra-long-acting insulin, with Sanofi's Lantus (insulin glargine), the world's biggest-selling insulin product. The Phase IIIa 1,030-patient study...Mon, 11 Jun 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=263212&full=1DUBLIN--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (VRTX) announced today new data from a long-term follow-up study that showed that the improvements in lung function (forced expiratory volume in one second, FEV1), respiratory symptoms and weight gain among people who were treated with KALYDECO (ivacaftor) for 48 weeks in one of two pivotal studies (STRIVE or ENVISION) were durable for...Fri, 08 Jun 2012 12:00:00 AM GMThttp://www.reuters.com/article/2012/06/06/us-roche-actemra-idUSBRE85506620120606SOUTH SAN FRANCISCO, Calif., Jun 05, 2012 (BUSINESS WIRE) -- Genentech, a member of the Roche Group (six:RO)(six:ROG)(otcqx:RHHBY), today announced data from the ADACTA study which showed that adult rheumatoid arthritis (RA) patients who received ACTEMRA (tocilizumab) as single-agent therapy (without other DMARDs) experienced a significantly greater improvement in disease activity (DAS28 score reduction...Thu, 07 Jun 2012 12:00:00 AM GMThttp://www.reuters.com/article/2012/05/25/us-europe-medicines-pradaxa-idUSBRE84O0H920120525Doctors and patients should be given clearer guidance on how to avoid bleeding risks when using Boehringer Ingelheim's new stroke prevention pill Pradaxa, European regulators said on Friday. The European Medicines Agency said data continued to confirm the positive benefit-risk balance of the anticoagulant medicine, despite cases of fatal bleeding, but advice on the risks should be strengthened. Pradaxa...Fri, 25 May 2012 12:00:00 AM GMThttp://www.rttnews.com/1886716/genentech-announces-groundbreaking-alzheimer-s-disease-prevention-trial.aspx?type=qfRoche Holding AG's Genentech unit has won the right to try its experimental Alzheimer's drug crenezumab on people with no signs of dementia - the first such trial to gauge whether early intervention can help prevent or slow the disease. The drug will be tested among members of an extended family of about 5,000 people from the Antioquia region of Colombia. They carry a gene that causes them to develop...Mon, 21 May 2012 12:00:00 AM GMThttp://www.rttnews.com/1880906/merck-kgaa-says-petacc-8-study-of-erbitux-shows-no-benefit-at-interim-analysis.aspxGermany's Merck KGaA said on Wednesday that Erbitux, one of its most important drugs, failed to help colon cancer patients after surgery in a late stage trial. A scheduled interim analysis of the so-called Petacc-8 study, which tested Erbitux in combination with standard chemotherapy as a treatment of colon cancer that has started spreading, showed no improvement in disease-free survival compared with...Wed, 09 May 2012 12:00:00 AM GMThttp://www.pharmatimes.com/Article/12-05-01/Avastin_and_Lucentis_equal_for_treating_wet_AMD_-_NIH_study.aspxBasel, Switzerland, May 01, 2012 (Thomson Reuters ONE via COMTEX) -- Novartis International AG / Recent publicly-funded CATT trial highlights serious safety concerns around unlicensed ocular bevacizumab use versus Lucentis . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. </p><p>- Two year data confirms an overall significantly...Wed, 02 May 2012 12:00:00 AM GMT